Oxurion NV (GB:0G99) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Oxurion NV has increased its share capital by EUR 150,000 through the conversion of convertible bonds by Atlas Special Opportunities, LLC, as part of a EUR 20 million commitment to develop innovative eye care therapeutics. This capital increase results in a total of 2,567,406 shares with voting rights, positioning Oxurion to target a potential market valued at USD 3-6 billion. The company continues to focus on advancing treatments for retinal diseases amid this financial bolstering.
For further insights into GB:0G99 stock, check out TipRanks’ Stock Analysis page.
